Inhaled Glucocorticoids and COPD Exacerbations by Singanayagam, A et al.
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 372;1 nejm.org january 1, 201592
for transfusion in our clinical setting.3 The bene-
fit of using the lactate level and Scvo2 to initiate 
and guide early resuscitation, including transfu-
sion, in patients with septic shock may be ques-
tioned after the results of recent randomized 
trials.4,5 As compared with the high-quality data 
from these trials, the results of any post hoc 
subgroup analyses that we may do are less valid.
Gordillo-Escobar et al. speculate that the age 
of blood and storage lesion could bias the results 
of our trial. Transfusion practice in patients with 
septic shock was not based on the age of blood 
at the TRISS trial sites. These factors may be im-
portant, and data from ongoing randomized tri-
als will help us to understand whether the age of 
blood affects the outcome of critically ill patients 
(Standard Issue Transfusion versus Fresher Red 
Blood Cell Use in Intensive Care [TRANSFUSE] 
trial [ClinicalTrials.gov number, NCT01638416] 
and the Age of Blood Evaluation [ABLE] trial [Cur-
rent Controlled Trials number, ISRCTN44878718]).
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Inhaled Glucocorticoids and COPD Exacerbations
To the Editor: In the Withdrawal of Inhaled 
Steroids during Optimized Bronchodilator Man-
agement (WISDOM) study, Magnussen et al. 
(Oct. 2 issue)1 report that the withdrawal of in-
haled glucocorticoids had no significant effect 
on exacerbations in patients with severe chronic 
obstructive pulmonary disease (COPD), a finding 
that prompted them to cast doubts about the use 
of these drugs in such patients. We are concerned 
about this conclusion because the follow-up of 
less than 1 year was probably not long enough to 
assess exacerbations, given that such events occur 
with an average frequency of 1.3 to 2 per year. In 
addition, there was a definite trend toward an 
increase in severe exacerbations after glucocorti-
coid withdrawal (P = 0.08), which we think con-
veys an important warning. Perhaps, patients with 
stage 3 disease (according to the Global Initiative 
for Chronic Obstructive Lung Disease [GOLD] 
criteria) should be analyzed separately from those 
with stage 4 disease to see whether they have dif-
ferent responses.2,3 The most worrisome find-
ings were the significant dose- and time-depen-
dent loss of forced expiratory volume in 1 second 
(FEV1) and deterioration in quality of life after 
the withdrawal of inhaled corticosteroids.
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To the Editor: Magnussen and colleagues re-
port that stepwise withdrawal of inhaled gluco-
corticoids had no adverse effect on exacerbation 
frequency in patients with severe COPD. The de-
cision to exclude from this study patients with no 
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previous exacerbations may have led to removal 
of the most important subgroup to evaluate. In 
such patients, inhaled glucocorticoids may have 
successfully prevented exacerbations, so the with-
drawal of therapy, even in a stepwise manner, 
could have led to increased exacerbations. The 
inclusion of these patients could have altered 
the noninferiority finding reported in this trial. 
The fact that inhaled glucocorticoids are widely 
prescribed in clinical practice suggests that phy-
sicians may see value in their use.1,2
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To the Editor: We are concerned that a readily 
identifiable subgroup of patients with COPD who 
participated in the WISDOM study were put at 
risk when their inhaled glucocorticoid was with-
drawn. Sputum evidence of eosinophilic airway 
inflammation is present in 20 to 30% of patients 
with COPD during stable periods and acute exac-
erbations.1 These patients have a good short-
term and long-term response to glucocorticoids, 
and a raised blood eosinophil count has been 
shown to be a good biomarker of this pattern of 
airway inflammation.1 An increased peripheral-
blood eosinophil count is associated with an in-
creased risk of death from COPD2 and with a 
better response to oral prednisolone in patients 
with a moderate3 or severe4 exacerbation. Patients 
with a raised blood or sputum eosinophil count 
may therefore have a poor response to the with-
drawal of inhaled glucocorticoids. The authors 
measured full blood counts and sputum inflam-
matory-cell counts in a subgroup of patients. We 
suggest that assessing the outcome of inhaled 
glucocorticoid withdrawal in patients who are 
stratified according to the baseline blood or spu-
tum eosinophil count is an important priority.
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The authors reply: Cosio et al. are concerned 
that our study follow-up may not have been long 
enough to assess an increased risk of exacerba-
tions because of a low annual frequency of such 
events. Our study was powered to show noninfe-
riority with regard to moderate or severe exacer-
bations on the basis of an estimated number of 
events to be observed, and there was no time-
dependent increase in these events (as shown in 
Fig. 2A of our article). As for the observed nu-
merical increase in severe exacerbations, this was 
a transient increase after inhaled glucocorticoids 
were completely stopped. However, as shown in 
Figure 2C of our article, this difference was not 
maintained, and the overall event rate was simi-
lar in the two groups. We present the analysis 
according to GOLD stage in Figure 3 of our arti-
cle, and there was no significant between-group 
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difference. The observed loss of FEV1 was neither 
a time-dependent nor a dose-dependent effect in 
the withdrawal group, as compared with the main-
tenance group. A difference of 38 ml between 
groups became apparent only after the final step 
of inhaled glucocorticoid withdrawal and did not 
change to a meaningful extent thereafter.
Singanayagam et al. point out that we included 
only patients receiving maintenance therapy 
with inhaled glucocorticoids who had a history 
of exacerbation in the previous year. This reflects 
current treatment recommendations. In the re-
cent Indacaterol: Switching Nonexacerbating Pa-
tients with Moderate COPD from Salmeterol/
Fluticasone to Indacaterol (INSTEAD) trial in-
volving patients with moderate COPD who had 
no exacerbations during the previous year, switch-
ing patients from a combination of a long-acting 
β-agonist (LABA) and an inhaled glucocorticoid 
to an ultra-long-acting LABA did not increase 
the exacerbation rate during 26 weeks of treat-
ment.1 We agree that clinicians prescribe inhaled 
glucocorticoids because they see value in their 
use, but there may be reasons other than the 
prevention of exacerbations for this practice, such 
as the convenience of combination inhalers.2
Brightling et al. suggest that we stratify our 
results according to the baseline blood eosino-
phil count. A major objective of the WISDOM 
trial was to identify a subgroup of patients who 
have a response to inhaled glucocorticoids,3 but 
so far we have not been able to identify a respon-
sive phenotype on the basis of data from our 
prespecified subgroups.
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Fractional Flow Reserve–Guided PCI
To the Editor: De Bruyne et al. (Sept. 25 issue)1 
conclude that the high rate of death within 7 days 
after randomization in the percutaneous coro-
nary intervention (PCI) group in their study was 
due to benign periprocedural infarctions, but there 
were more myocardial infarctions in the medical-
therapy group after the initial 7 days following 
randomization. However, after 7 days, there were 
more revascularizations in the medical-therapy 
group; this suggests that there were more peri-
procedural infarctions.2 Thus, the high rate of 
myocardial infarctions after the initial 7 days fol-
lowing randomization in the medical-therapy 
group could also be caused by the same benign 
periprocedural infarctions, since there was no dif-
ference in overall mortality.2 Unfortunately, the 
percentage of late myocardial infarctions caused 
by periprocedural infarctions was not reported.
Furthermore, the primary outcome in this 
study was driven mainly by urgent revasculariza-
tion, which could have been confounded by the 
open-label nature of the study. Since patients in 
the medical-therapy group knew that they had 
untreated stenosis, they were more likely to re-
port symptoms.3 Coupled with bias from treat-
ing physicians, this would lead to a higher inci-
dence of hospitalization, cardiac catheterization, 
and ultimately revascularization.4 Therefore, a 
double-blind, controlled trial is required to de-
termine the true effect of fractional flow re-
serve–guided PCI on urgent revascularization.5
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